Company: IPHYF
Filing Date: 2025-04-24
Form Type: 6-K
Source: 0001598599-25-000032
Chunk: 0

Company: Innate Pharma SA
Filing Date: 2025-04-24
Form: 6-K
Chunk 0
---
### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549 FORM 6-K
<div align='center'>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>

#### Date of report: April 24, 2025

#### Commission File Number: 001-39084

#### Innate Pharma S.A.
<div align='center'>(Translation of registrant's name into English)</div>

#### Innate Pharma S.A.

#### 117 Avenue de Luminy—BP 30191

#### 13009 Marseille, France

#### + 33 (0) 4 30 30 30
<div align='center'>(Address of principal executive office)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ]

### INCORPORATION BY REFERENCE
This Report on Form 6-K and Exhibit 99.1 to this Report on Form 6-K (excluding the quotation from Jonathan Dickinson, Chief Executive Officer at Innate Pharma) shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-276164) and registration statement on Form S-8 (File No. 333-282031) of Innate Pharma S.A. (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.

### EXHIBIT INDEX

#### Exhibit

#### Description
99.1 Press Release dated April 24, 2025

### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

#### INNATE PHARMA S.A.
Date: April 24, 2025 By: /s/ JONATHAN DICKINSON Name: Jonathan Dickinson

Title: Chairman of the Executive Board and Chief Executive Officer